We caught up with Dr Lisanne de Koster, (Radboud University Medical Center, Nijmegen, The Netherlands) to discuss her study which investigated whether the use of FDG-PET/CT could prevent unnecessary diagnostic thyroid surgery.
The abstract ‘Efficacy of 18F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial’ (Abstract 49) was presented at the European Thyroid Association (ETA) Annual Meeting 2021, 4-7 September 2021.
Questions
1. How is papillary thyroid cancer currently diagnosed and prognosed? (0:15)
2. Why is it important to avoid unbeneficial diagnostic thyroid lobectomies and how might fludeoxyglucose (18F-FDG)-PET/CT imaging improve preoperative differentiation? (0:53)
3. What impact did FDG-PET/CT imaging have on unbeneficial diagnostic thyroid lobectomies? (2:36)
4. Are there any nodule types where FDG-PET/CT imaging was more or less useful in pre-operative nodule differentiation? (03:14)
5. What impact will these findings have on patients and is there anything more that needs to be done to inform clinical management guidelines (04:13)
Disclosures: Dr Lisanne de Koster has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the European Thyroid Association (ETA) Annual Meeting 2021, 4-7 September 2021.
18F-FDG = 2-deoxy-2-[fluorine-18]fluoro-D-glucose; CT = computed tomography; PT = positron emission.
Reference
de Koster EJ, De Geus-Oei L-F, Brouwers AH, et al. 49: Efficacy of 18F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial. Eur Thyroid J 2021;10(Suppl. 1):13.
